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Leishmaniasis  is  a parasitic  disease  caused  by the  intramacrophage  protozoa  Leishmania  spp.  and  may  be
fatal  if left  untreated.  Although  pentavalent  antimonials  are  toxic  and  their mechanism  of action  is  unclear,
they  remain  the  ﬁrst-line  drugs  for treatment  of leishmaniasis.  An effective  therapy  could  be  achieved
by  delivering  antileishmanial  drugs  to the  site  of  infection.  Compared  with  free  drugs,  antileishmanial
agent-containing  liposomes  are  more  effective,  less  toxic  and  have  fewer  adverse  side effects.  The  aim  of
this  study  was  to develop  novel  meglumine  antimoniate  (MA)-containing  liposome  formulations  and  to
analyse  their  antileishmanial  activity  and  uptake  by macrophages.  Determination  of the  50%  inhibitory
concentration  (IC50)  values  showed  that  MA-containing  liposomes  were  ≥10-fold  more  effective  than  the
free  drug,  with  a 5-fold  increase  in  selectivity  index,  higher  activity  and reduced  macrophage  toxicity.
The  concentration  required  to  kill  100%  of intracellular  amastigotes  was ≥40-fold  lower  when  MA was
encapsulated  in  liposomes  containing  phosphatidylserine  compared  with  the  free  drug.  Fluorescence
microscopy  analysis  revealed  increased  uptake  of ﬂuorescent  liposomes  in  infected  macrophages  after
short  incubation  times  compared  with  non-infected  macrophages.  In conclusion,  these  data  suggest  that
MA  encapsulated  in  liposome  formulations  is more  effective  against  Leishmania-infected  macrophages
than  the non-liposomal  drug. Development  of liposome  formulations  is  a valuable  approach  to the
treatment  of  infectious  diseases  involving  the  mononuclear  phagocyte  system.
d th© 2011 Elsevier B.V. an
. Introduction
The leishmaniases are a complex of diseases caused by at least
7 species of the protozoan parasite Leishmania. Human leishma-
iasis occurs worldwide but is mainly localised to the tropics and
ubtropics, with a prevalence of 12 million cases and an incidence
f 0.5 million cases of visceral leishmaniasis (VL) and 1.5 million
ases of cutaneous leishmaniasis (CL). Globally there are an esti-
ated 70 000 deaths each year and 350 million people are at risk
f infection [1]. Generally, VL is fatal if untreated, whereas CL fre-
uently self-cures, leaving disﬁguring scars. Despite its increasing
orldwide incidence, leishmaniasis has become one of the so-
alled neglected diseases, generating little interest from ﬁnancial
onors, public health authorities, pharmaceutical companies and
∗ Corresponding author. Present address: Núcleo de Doenc¸ as Respi-
atórias–Centro de Virologia, Instituto Adolfo Lutz, Av. Dr Arnaldo 355, Cerqueira
ésar,  CEP: 01246-902, São Paulo, SP, Brazil. Tel.: +55 11 3068 2913.
E-mail  address: samanta@usp.br (S.E. Treiger Borborema).
924-8579 © 2011 Elsevier B.V. and the International Society of Chemotherapy. 
oi:10.1016/j.ijantimicag.2011.05.012
Open accee International Society of Chemotherapy. 
professionals that is required for research and the prevention and
control of a disease [2].
The  mainstays of leishmaniasis treatment are pentavalent anti-
monials such as meglumine antimoniate (MA) (Glucantime®).
These antimonials were ﬁrst introduced in 1945 and remain effec-
tive treatments for some forms of leishmaniasis. However, long
periods of parenteral administration, variable efﬁcacy against VL
and CL, and the emergence of signiﬁcant resistance are all factors
that limit the usefulness of these drugs [3]. Moreover, they can have
severe side effects and their mode of action is still unclear. Further-
more, effective leishmaniasis vaccines currently do not exist [4].
The high prevalence of leishmaniasis and the emergence of resis-
tance to conventional drugs demonstrate the need to develop and
discover new, less toxic and more efﬁcient treatments [5]. Develop-
ment of formulations of antileishmanial agents using nanocarriers
such as liposomes is an attractive alternative [6].
Open access under the Elsevier OA license.Liposomes are well established to be non-toxic, non-
immunogenic and biocompatible. They have been shown to
improve the efﬁcacy and to reduce the systemic toxicity of
drugs [7], speciﬁcally as carriers for antifungals, antibiotics [8]
ss under the Elsevier OA license.
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nd anticancer drugs [9]. Liposomes are preferentially taken
p through the mononuclear phagocyte system, predominantly
y the macrophages of the liver and spleen, which are the main
eservoirs of parasites in VL. Therefore, use of liposomes represents
 rational strategy to target these tissues with antileishmanial
gents to treat this parasitic disease more efﬁciently. Several
tudies have demonstrated that liposome-encapsulated MA  is
igniﬁcantly more effective in vitro [10] and in vivo than the
ree drug [11,12]. Conventional processes for the preparation of
iposomal MA  showed signiﬁcant technological disadvantages,
uch as short-term stability and low encapsulation of the drug
13]. We  tried to overcome these difﬁculties by incorporation
f negatively charged phospholipids into liposomes of reduced
ize with increased macrophage uptake and drug encapsulation
fﬁciency, and also to prepare liposome formulations that can be
tored frozen with longer storage stability. Thus, the aims of this
tudy were to develop MA-containing liposome formulations and
o analyse both their antileishmanial activity and their uptake by
acrophages in vitro, which have been the subject of only few
tudies by other research groups.
. Material and methods
.1.  Chemicals
Opti-MEM® I reduced serum medium, Schneider’s Drosophila
edium with l-glutamine, RPMI 1640 with l-glutamine and
oetal bovine serum (FBS) were from Gibco (Basel, Switzerland).
holesterol was from Fluka (Buchs, Switzerland) and resazurin
7-hydroxy-3h-phenoxazin-3-one 10-oxide sodium salt) and phos-
hatidylserine (3-sn-phosphatildyl-l-serine)  were from Sigma (St
ouis, MO).
Soy  phosphatidylcholine (PC) was obtained from L. Meyer
Hamburg, Germany). 4′,6-Diamidino-2-phenylindole dihy-
rochloride (DAPI) was from Roche Diagnostics GmbH
Mannheim, Germany) and 1,1′-dioctadecyl-3,3,3′,3′-
etramethylindocarbocyanine perchlorate (DiI) was from
olecular Probes (Eugene, OR). d,l--Tocopherol was  obtained
rom Merck (Darmstadt, Germany) and MA  (Glucantime®,
00 mg/mL) was obtained from Sanoﬁ-Aventis (São Paulo, Brazil).
.2. Animals and cells
C57BL/6  mice were supplied by the animal breeding facility at
he University of Zurich (Zurich, Switzerland) and were maintained
n sterilised cages in a controlled environment. Mice received water
nd food ad libitum. All of the animal procedures were performed
ith the approval of the Veterinary Department of the Kanton
ürich (permit 215/2008). RAW 264.7 murine macrophage cells
TIB-71) (American Type Culture Collection, Manassas, VA) were
ultivated in RPMI 1640 supplemented with 10% FBS and 1% antibi-
tics (penicillin and streptomycin). Cells were maintained at 37 ◦C
n a humidiﬁed atmosphere containing 5% CO2 as described by Tem-
one et al. [14]. Isolated Leishmania (Leishmania) major amastigotes
MHOM/IL/81/FEBNI) were a kind gift from Prof. M.  Kopf (Institute
f Integrative Biology, Molecular Biomedicine, Swiss Federal Insti-
ute of Technology, Zurich, Switzerland). Parasites were cultivated
n Schneider’s Drosophila medium supplemented with 1% antibi-
tics and 20% FBS. Cells were maintained at 27 ◦C as described by
ezzi et al. [15].
.3.  Preparation and characterisation of meglumine
ntimoniate-containing liposomes
Liposomes were prepared as described previously [16]. Brieﬂy,
ipid mixtures of either PC (200 mg/mL), cholesterol (40 mg/mL) of Antimicrobial Agents 38 (2011) 341– 347
and  d,l--tocopherol (1.1 mg/mL; molar ratio 10:4:0.1) (L) or of
PC, phosphatidylserine (PS) (20 mg/mL), cholesterol and d,l--
tocopherol (molar ratio 10:1:4:0.1) (PS-L) were prepared. For the
ﬂuorescent liposomes, 0.02 mol/mL of DiI was  added to the lipid
mixtures (DiI-L and DiI-PS-L, respectively). Dry  lipid ﬁlms were
then dispersed in a physiological phosphate–mannitol buffer (PB-
man) (20 mM,  230 mM mannitol, pH 7.4) and supplemented with
either the corresponding amount of MA (10.4 mg/mL) or with PB-
man  for the empty control liposomes. The resulting multilamellar
vesicles were freeze–thawed in three cycles of liquid nitrogen and
40 ◦C water and then subjected to repetitive extrusion through ﬁlter
membranes (NucleoporeTM; Sterico, Dietikon, Switzerland) with
400 nm (5×), followed by 100 nm (8×) pore sizes, using a LIPEXTM
extruder (Northern Lipids Inc., Burnaby, BC, Canada) to obtain small
unilamellar vesicles.
Non-encapsulated MA  was  removed by dialysis (Spectra/Por
tube, 12–14 KDa molecular weight cut-off; Spectrum Laboratories
Inc., Rancho Dominguez, CA) at 4 ◦C in PB-man buffer (1:100, v/v).
Liposomal preparations were ﬁlter-sterilised using 0.45 m ﬁlters
and the aliquots were then frozen and stored at −80 ◦C. Liposome
size and homogeneity were measured with a Nicomp 370 laser
light-scattering particle sizer (Nicomp Inc., Santa Barbara, CA). MA-
containing liposomes were classiﬁed as Gluc-L or Gluc-PS-L after
complete processing.
2.4.  Antimony (Sb) determination by instrumental neutron
activation analysis (INAA)
Aliquots of either MA  liposomes or Sb solutions were irradi-
ated at the IEA-R1 nuclear reactor facility of IPEN-CNEN/SP (Sao
Paulo, Brazil) at a thermal neutron ﬂux of 0.8–1.0 × 1012 n/cm2/s
for 15 min  as described by Osso et al. [17]. Concentrations of Sb
in the irradiated samples were determined after 2 days of cool-
ing by measuring 122Sb (564 keV). As a reference, Sb2O3 (Merck)
concentrations were quantiﬁed to determine the accuracy of the
INAA. Each sample was counted for 300–1800 s live time on an
HPGe detector coupled to a Genie-PC software program (Canberra
Industries Inc., Meriden, CT). Concentrations of Sb were determined
by comparison with the standards that contained comparable
amounts of the elements and were irradiated under the same condi-
tions as the samples. Precision of the measurements was  calculated
as the statistical counting error of the net peak area.
Encapsulation efﬁciency was determined by measuring Sb con-
centrations in the liposomal dispersions before and after separation
of the non-encapsulated drug. The values were calculated as the
percentage of the drug that was  incorporated into the liposomes.
2.5.  Macrophage cytotoxicity assay
RAW 264.7 macrophages were seeded in 96-well microplates
(Gibco) at a density of 1 × 104 per well and were grown under
normal culture conditions. After 24 h, the medium was replaced
with either the drug or liposomes at various concentrations.
Cells were incubated for 48 h at 37 ◦C in 5% CO2. The cytotoxic
effects of the test compounds were determined using the resazurin
assay according to the manufacturer’s recommendations. Brieﬂy,
resazurin-containing medium (1:20, v/v) was  added to each well.
After 3 h incubation at 37 ◦C in 5% CO2, ﬂuorescence was  measured
at a 590 nm emission wavelength and a 560 nm excitation wave-
length in a SpectraMax® M5 Microplate Reader (Molecular Devices,
Sunnyvale, CA). Data analysis was  performed using GraphPad Prism
5.03 software (GraphPad Software Inc., La Jolla, CA) using the mean
of three experiments in duplicate.
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Table 1
Liposome characterisation: initial weight ratio of lipid to encapsulated meglumine
antimoniate (MA) (Ratioi), mean size and encapsulation efﬁciency (EE).
Liposomes Ratioi (w/w) Mean diameter (nm) Ee (%)
Gluc-L 0.04 142.3 ± 61.4 25
Gluc-PS-L 0.04 141.0 ± 96.2 38
Gluc-L, MA-containing liposomes composed of phosphatidylcholine/cholesterol;
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Table 2
Antileishmanial activity against Leishmania (Leishmania) major and cytotoxicity in
non-infected RAW 246.7 macrophages of meglumine antimoniate (MA)-containing
liposomes  (Gluc-L or Gluc-PS-L) and free drug (MA).
Drug IC50 (M) (95% CI)a SI
Amastigotes Promastigotes Macrophages
Gluc-L 10.5 (5–21) >9000 9240 (7860–10 850) 880
Gluc-PS-L 25 >12 000 5890 (4940–7030) 235
MA 93 (65–132) >234 000 16 420 (15 060–17 910) 177
Gluc-L, MA-containing liposomes composed of phosphatidylcholine/cholesterol;
Gluc-PS-L, MA-containing liposomes composed of phosphatidyl-luc-PS-L, MA-containing liposomes composed of phosphatidyl-
holine/phosphatidylserine/cholesterol.
.6. Leishmania (L.) major cytotoxicity assays
Promastigotes were seeded in 96-well microplates at a density
f 1 × 106 cells/well. Test compound solutions were diluted with
rowth medium using two-fold serial dilutions and were incu-
ated with the parasites for 24 h at 24 ◦C. Parasite viability was
etermined using the resazurin assay as described previously. Via-
ility (100%) was expressed based on the ﬂuorescence units of the
ntreated positive controls after normalisation.
Activity against L. (L.) major intracellular amastigotes was  deter-
ined in infected macrophages. Macrophages were isolated from
he peritoneal cavities of C57BL/6 mice (eight males) by lavage
ith phosphate-buffered saline (PBS). Cells were then seeded
nto 24-well plates containing glass cover slips at a density of
 × 104 cells/well and were incubated for 24 h prior to infection.
eishmania (L.) major promastigotes were added at a ratio of
:10 (macrophage/promastigote) and were incubated for 24 h.
on-internalised parasites were removed by washing once with
edium followed by incubation with the test compounds for 5
ays at 37 ◦C in 5% CO2. Cells were ﬁxed in methanol, stained with
iemsa stain and observed under a light microscope to determine
he number of intracellular parasites. The number of amastigotes
as determined in 400 macrophages from drug-treated and control
ultures. The number of counted amastigotes in the untreated cul-
ures was considered to be 100% for calculation of the percentage
f suppression of parasites in the drug-treated cultures [10]. The
0% inhibitory concentration (IC50) was calculated with a sigmoid
ose–response model that was generated with GraphPad Prism
.03 software using the mean of two experiments in duplicate.
.7.  Uptake of ﬂuorescent liposomes by RAW 264.7 macrophages
RAW  264.7 macrophages were infected with L. (L.) major pro-
astigotes as described previously. Opti-MEM I medium (2% FBS)
ontaining ﬂuorescent liposomes (DiI-L or DiI-PS-L, 10 L or 25 L
iposomes in 500 L of medium) was then added and the plates
ere incubated up to 24 h at 37 ◦C in 5% CO2. Cells were then
ashed twice with PBS, ﬁxed with 3% formaldehyde and stained
ith DAPI (1 g/mL). Finally, cells were washed with PBS and
iposome uptake was examined using an Olympus BioSystems
uorescence microscope (OBS IX81; Olympus, Tokyo, Japan). To
uantify the uptake of ﬂuorescent liposomes by macrophages, the
umber of ﬂuorescent cells in a total of 200 counted macrophages
as determined. The number of macrophages without ﬂuorescence
as considered 100% when calculating the percentages of uptake.
he ﬁgures were prepared using Adobe Photoshop and data anal-
sis was conducted with GraphPad Prism 5.03 software using the
ean of two experiments in duplicate.
. Results.1. Liposome characterisation
The  physicochemical parameters of the liposomes were evalu-
ted following drug entrapment. Table 1 summarises the resultscholine/phosphatidylserine/cholesterol; IC50, 50% inhibitory concentration;
CI,  conﬁdence interval; SI, selectivity index (IC50 RAW 246.7 cells/IC50 amastigotes).
a Values (mean and 95% CI) derived from three independent experiments.
of the analysis of the mean diameters of the liposome prepa-
rations following removal of non-encapsulated drug. All of the
liposomes had mean diameters of <150 nm. Size reduction and
population homogeneity were achieved by sequential repeated
extrusion through polycarbonate membranes. The encapsulation
efﬁciency was higher when the vesicles carried a negatively
charged phospholipid such as PS. Whilst the Gluc-L liposomes had
an encapsulation efﬁciency of ca. 25%, the efﬁciency increased to
38% with Gluc-PS-L. Preparation of the liposomes in a mannitol-
containing buffer allowed them to be stored frozen and lyophilised
with longer storage stability, an important property for distribution
in remote areas with human Leishmania infections [18,19].
3.2.  Antileishmanial and cytotoxic activity of meglumine
antimoniate-containing liposomes
The cytotoxic activity of the different drug preparations against
Leishmania promastigotes was analysed. As summarised in Table 2,
evaluation of IC50 demonstrated that the promastigotes were not
susceptible to either free MA  or the liposome-encapsulated drug.
The exact IC50 concentrations could not be determined because the
small internal volume of liposomes limits both the capacity of drug
transportation and the concentration of the drug.
Instead, L. (L.) major promastigotes were more susceptible to
Sb3+ (potassium antimony tartrate trihydrate) and Sb5+ [potas-
sium hexahydroxoantimonate (V)] solutions, with IC50 values of
0.017 mM (0.013–0.022 mM)  and 1.56 mM  (1.26–1.93 mM), respec-
tively.
Analysis of the cytotoxic effects on Leishmania amastigotes
revealed that the tested compounds were active in the micromo-
lar concentration range. Gluc-L treatment inhibited intracellular
amastigotes with an IC50 value of 10.5 M,  whereas the IC50 value
for free MA was 93 M (Table 2; Fig. 1). Gluc-PS-L had a leish-
manicidal activity of 100%, resulting in the death of all L. (L.) major
amastigotes at the lowest applied concentration of 25 M. A reduc-
tion in the drug concentrations used to achieve the IC50 is required
to improve this assay. This drug concentration effectively elimi-
nated the intracellular parasite and was  signiﬁcantly more active
than the standard drug. The dose–response curves for the deter-
mination of the IC50 values of MA and MA-containing liposome
formulations in mouse peritoneal macrophages infected with L. (L.)
major amastigotes are shown in Fig. 1.
These results demonstrate that the in vitro activity against
amastigotes of the liposome-encapsulated MA  was  ≥10-fold more
effective than free MA.  The cytotoxicity assay also revealed that
MA-containing liposomes were two  to three times more toxic
towards macrophages than the free drug, resulting in IC50 values of
9.2 mM and 5.9 mM,  respectively. Furthermore, the antimony salt
solutions, Sb3+ with an IC50 of 40.7 M (19.9–83.1 M)  and Sb5+
with an IC50 of 64.3 M (33.5–123.4 M),  were more active in the
amastigotes than MA,  which had an IC50 of 93 M.
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Fig. 1. Dose–response curve for determination of the 50% inhibitory concentration
(IC50) of meglumine antimoniate (MA) (Glucantime) or MA-containing liposome
formulations (Gluc-L) in mouse peritoneal macrophages infected with Leishmania
(Leishmania) major amastigotes. Cells were treated for a total of 5 days. Values
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amean  ± standard deviation) are derived from three independent experiments in
uplicate.
Microscopic observation of the macrophages conﬁrmed the
eishmanicidal activity of the liposome-encapsulated MA on the L.
L.) major amastigotes, showing a complete absence of amastigotes
n the macrophages after treatment with 13 M of Gluc-L. Fig. 2A
hows two Giemsa-stained control macrophages that were infected
ith Leishmania amastigotes and received no drug treatment,
howing the characteristic localisation of the parasites around the
ig. 2. Microscopic images of mouse peritoneal macrophages infected with Leishmania (Lei
il  immersion (magniﬁcation ×1000): (A) control, untreated cells (macrophages infected
eglumine antimoniate (MA) (macrophages infected with amastigotes, arrows); (C) paras
acrophages after treatment with 13 M of Gluc-L. Gluc-PS-L and Gluc-L indicate MA-cont
nd phosphatidylcholine/cholesterol, respectively. of Antimicrobial Agents 38 (2011) 341– 347
nucleus. MA at a concentration of 31 M (Fig. 2B) was not active
enough to eliminate all of the parasites. Fig. 2C and D are rep-
resentative examples showing the absence of amastigotes in the
macrophages after treatment with 13 M of Gluc-PS-L and Gluc-L,
respectively. The absence of amastigotes or a signiﬁcant reduction
in number compared with the untreated control suggests leish-
manicidal activity.
3.3.  Uptake of ﬂuorescent liposomes by Leishmania (L.)
major-infected RAW 264.7 macrophages
Using ﬂuorescence microscopy, high cell ﬂuorescence of both
types of DiI-labelled liposomes (DiI-L and DiI-PS-L) was  observed
at the onset of incubation, indicative of liposome uptake by L. (L.)
major-infected RAW 264.7 macrophages. As shown in Fig. 3A and
B, >80% of the infected macrophages had taken up ﬂuorescent lipo-
somes after 10 min  of incubation. Saturation occurred after 1 h of
incubation when almost 100% of the cells displayed ﬂuorescence.
In contrast, liposome uptake by non-infected macrophages was
slower during the ﬁrst 2–4 h but reached levels similar to those
of the infected cells at later incubation times. Moreover, accumu-
lation of ﬂuorescent liposomes of all types remained high in the
macrophages after 24 h of incubation (Fig. 3C). Signiﬁcant differ-
ences in uptake between the empty PS liposomes (DiI-PS-L), empty
liposomes (DiI-L) and the MA-containing liposomes (DiI-Gluc-L)
were not observed. Leishmania infection appeared to change the
liposome association and uptake proﬁle, probably by activation of
the phagocytic processes of the macrophages. These observations
are in accordance with the results of a previous study of liposome
uptake in infected macrophages by Tempone et al. [10].
shmania) major amastigotes in vitro and stained with Giemsa reagent, viewed under
 with amastigotes, arrows); (B) macrophages following treatment with 31 M of
ite-free macrophages after treatment with 13 M of Gluc-PS-L; and (D) parasite-free
aining liposomes composed of phosphatidylcholine/phosphatidylserine/cholesterol
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Fig. 3. Uptake of DiI-labelled liposomes by Leishmania (Leishmania) major-infected and non-infected RAW 264.7 macrophages incubated for various lengths of time and
analysed by ﬂuorescence microscopy. The percentage of ﬂuorescence-positive cells was calculated as described in Section 2.7. (A and B) Comparison of the uptake
of DiI-L (A) and DiI-PS-L (B) in infected versus non-infected macrophages; (C) uptake of DiI-liposomes (DiI-L, DiI-PS-L and DiI-Gluc-L) in infected macrophages. DiI,
1,1′-dioctadecyl-3,3,3′ ,3′-tetramethylindocarbocyanine perchlorate; DiI-L, empty DiI-labelled phosphatidylcholine/cholesterol liposomes; DiI-PS-L, empty DiI-labelled phos-
phatidylcholine/phosphatidylserine/cholesterol liposomes; DiI-Gluc-L, DiI-labelled meglumine antimoniate-containing liposomes.
Fig. 4. Fluorescence microscopy images of infected and non-infected RAW 264.7 macrophages incubated with DiI-stained liposomes. Cells were incubated with DiI lipo-
somes  (red) for 1 h (1.83 mol  of lipid/well and labelled with 0.02 mol  of DiI) and were visualised with ﬂuorescence microscopy (magniﬁcation ×600): (A) Leishmania
(Leishmania) major-infected RAW 264.7 cells incubated with DiI-L; (B) non-infected RAW 264.7 cells incubated with DiI-L; (C) L. (L.) major-infected RAW 264.7 cells
incubated with DiI-PS-L; (D) non-infected RAW 264.7 cells incubated with DiI-PS-L; and (E) L. (L.) major-infected RAW 264.7 cells incubated with DiI-Gluc-L (red) for
18  h (magniﬁcation ×1000). Images show cell nuclei staining using DAPI as a DNA marker (blue). The white arrowheads in (E) indicate areas with a high concentration
of amastigotes. DiI, 1,1′-dioctadecyl-3,3,3′ ,3′-tetramethylindocarbocyanine perchlorate; DAPI, 4′ ,6-diamidino-2-phenylindole dihydrochloride; DiI-L, empty DiI-labelled
phosphatidylcholine/cholesterol liposomes; DiI-PS-L, empty DiI-labelled phosphatidylcholine/phosphatidylserine/cholesterol liposomes; DiI-Gluc-L, DiI-labelled meglumine
antimoniate-containing liposomes. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of the article.)
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Comparison of liposome uptake by infected and non-infected
acrophages is illustrated in Fig. 4. The concentration of ﬂuores-
ent liposomes was higher in L. (L.) major-infected macrophages,
nd the ﬂuorescence intensity in the cells was enhanced after a
horter incubation time. Such effects were markedly lower when
on-infected macrophages were used as a reference. The ﬂuores-
ence appeared as a heterogeneous population of red spots within
he boundaries of the cell, presumably in the cytoplasm.
When liposome uptake was examined at a higher magniﬁcation,
s shown in Fig. 4E, image analysis revealed that the ﬂuores-
ent liposomes were predominantly stored inside the cells and
istributed in a perinuclear fashion over the cytoplasm in an
nhomogeneous pattern. We  presume that they were localised to
ndosomes and lysosomes, conﬁrming the intracellular distribu-
ion of the liposomes [20].
.  Discussion
In this study, it was veriﬁed that, when encapsulated in lipo-
omes composed of either PC/cholesterol or PC/PS/cholesterol, the
ntileishmanial drug MA  is able to target and eliminate intracellu-
ar amastigotes of L. (L.) major in infected macrophages. These data
emonstrate that MA-containing liposomes have strong in vitro
ctivity against intracellular amastigotes and are ≥10-fold more
ffective than the free drug. It was also observed that L. (L.) major
romastigotes were not susceptible to the free drug and MA-
ontaining liposomes. On the contrary, L. (L.) major amastigotes
ere ≥100 times more susceptible to the free and encapsulated
rugs than the promastigote form (Table 2; Fig. 1). IC50 data of
he free antimony solutions and MA  are consistent with results
escribed elsewhere [21,22]. These ﬁndings could be explained by
he hypothesis that, to be active against Leishmania, the pentava-
ent antimony has to enter the host cell, cross the phagolysosomal
embrane and act against the intracellular amastigotes. It is also
ighly likely that the Sb5+ has to be converted to the Sb3+ form to
e active, acting as prodrugs [6,21]. The greater susceptibility of
ntracellular amastigotes to Sb5+ than promastigotes suggests that
he reductive activation of the drug occurs within the intracellular
mastigotes [23,24]. However, as parasites in both stages can take
p Sb3+ and Sb5+, the insensitivity of promastigotes to Sb5+ cannot
e attributed to drug exclusion [25]. These results are not incom-
atible with these ﬁndings and it is conceivable that the reduction
ccurs in both the host and the parasite.
The selectivity index also increased ﬁve-fold for MA-containing
iposomes, showing higher antileishmanial activity with reduced
acrophage toxicity. The concentration required to kill 100% of
he intracellular amastigotes was ≥40-fold lower with MA encap-
ulated in PS-containing liposomes than with the free drug. Thus,
hese data suggest that liposomal MA  is more effective than
he non-liposomal drug against Leishmania-infected macrophages.
imilar results were also found in that MA  encapsulated in PS-
ontaining liposomes was 16-fold more effective than the free
rug against infected macrophages [10]. Jaafari et al. [26] eval-
ated liposomes containing paromomycin sulfate (PM) against L.
ajor promastigotes and amastigotes and reported that they were
hree to four times more effective than PM in solution and infected
ice were completely cured after topical treatment. Miltefosine,
he ﬁrst effective oral drug against VL, exhibited an IC50 at 7.8 M
gainst Leishmania donovani amastigotes, whereas entrapment in
iposomes of PC-stearylamine (SA) was completely inactive [27].
The  small size of the liposomes and the inclusion of neg-
tive charges may  inﬂuence the targetability of the liposomes,
ossibly due to the ligand-binding properties to macrophage scav-
nger receptors (SRs). Tempone et al. [10] previously demonstrated
hat PS-based liposomes targeted intracellular Leishmania (L.) of Antimicrobial Agents 38 (2011) 341– 347
chagasi amastigotes via SRs in macrophages to deliver antimony.
Leishmania-infected macrophages have been shown to upregulate
the SRs CD36, SRB-1 and MARCO. Therefore, SRs may  represent a
promising target for PS liposomes [10,28].
These results further demonstrate that liposomes are able to
target drugs to macrophages and deliver them to phagolysosomes.
Negatively charged liposomes may  target the parasitophorous vac-
uoles inside of macrophages by a mechanism related to annexins,
the hydrophilic proteins that reversibly bind negatively charged
phospholipids and act as bridging molecules in the fusion of vesicles
[10]. Inside of this compartment, the liposomes are disrupted by an
acid-phase phospholipase and undergo phagolysosomal degrada-
tion, ultimately releasing their contents into the cytoplasm [20,29].
Surprisingly, we did not observe signiﬁcant differences between
the uptake of negatively charged and uncharged liposomes. How-
ever, charged liposomes are known to be phagocytosed at higher
rates owing to speciﬁc or electrostatic interactions between cells
and vesicles [30]. Indeed, inclusion of PS can lead to the preferred
recognition of liposomes by cells of the mononuclear phagocytic
system [31,32].
In  contrast, Dey et al. [33] reported that cationic liposomes
with PC and SA had leishmanicidal activity both in vitro and in
vivo. Entrapment of sodium stibogluconate (PC-SA-SSG) enhanced
their potentiality against chronic VL in an in vivo murine model
[34]. More recently, Roychoudhury et al. [35] discussed that PC-
SA-SSG conferred cure against SSG-unresponsive L. donovani in
mice by complete suppression of disease-promoting interleukin-
10 and transforming growth factor-beta (TGF), upregulation of
Th1 cytokines and expression of macrophage microbicidal nitric
oxide.
Moreover, the physicochemical characteristics of liposomes can
strongly inﬂuence their targetability. Dynamic laser light scatter-
ing analysis showed that all of the liposome formulations had a
mean diameter size of <150 nm.  Schettini et al. [11] evaluated the
effects of treatment with a 400 nm liposomal formulation of MA
in dogs with VL and observed three-fold higher antimony levels in
the bone marrow of dogs when compared with a formulation with
large-sized (1200 nm)  liposomes. Ribeiro et al. [36] treated infected
dogs with this smaller-sized liposomal MA and also observed a sig-
niﬁcant reduction in bone marrow parasite burden after 5 months
of treatment. They also observed signiﬁcantly lower parasite loads
in the cervical lymph nodes, liver and spleen of the animals. In
addition, liposomes containing antimonial drugs with mean diam-
eters of <100 nm were more effective than the large-sized vesicles
in reducing the number of Leishmania parasites in the bone marrow
of mice [37].
The  results of ﬂuorescence microscopy studies showed an
increased uptake of ﬂuorescence-labelled liposomes by infected
macrophages after short incubation times compared with non-
infected macrophages. The parasitic infection may  alter both the
metabolic activity of the macrophages and their ability to ingest
particulate material, thereby modifying the phagocytic activity and
intracellular trafﬁcking of liposomes. Liposomes were still observed
in the cells >24 h after addition, demonstrating the persistent avail-
ability of the drug in the host cell, a factor that may  be essential for
antileishmanial activity.
In  conclusion, these data demonstrate the increased effec-
tiveness of liposome-encapsulated MA  against the intracellular
amastigotes of L. (L.) major parasites compared with the free
standard therapeutic drug, resulting in an improvement of the
selectivity index. Uptake of MA  encapsulated in various types of
liposomes was  signiﬁcantly increased in infected macrophages.
Nevertheless, further in vivo studies are required to evaluate both
the speciﬁc interactions of the liposomes with the parasites and
host cells as well as the therapeutic activity of liposomal MA.  In
addition, this study emphasises the potential use of drug delivery
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